Bank Of America Corp Cyma Bay Therapeutics, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $1.75 Million - $3.39 Million	-138,563 Reduced 76.25%	43,156 $1.02 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $2.57 Million - $3.77 Million	-343,974 Reduced 65.43%	181,719 $1.99 Million
Q1 2023 May 12, 2023	BUY	$5.88 - $9.59 $2.46 Million - $4.01 Million	417,851 Added 387.47%	525,693 $4.58 Million
Q4 2022 Feb 10, 2023	BUY	$3.22 - $6.27 $112,912 - $219,863	35,066 Added 48.18%	107,842 $676,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $141,361 - $216,890	-51,033 Reduced 41.22%	72,776 $255,000
Q2 2022 Aug 12, 2022	BUY	$1.72 - $3.39 $84,852 - $167,238	49,333 Added 66.24%	123,809 $365,000
Q1 2022 May 16, 2022	SELL	$2.77 - $3.64 $33,209 - $43,639	-11,989 Reduced 13.87%	74,476 $231,000
Q4 2021 Feb 08, 2022	SELL	$3.23 - $4.6 $60,472 - $86,121	-18,722 Reduced 17.8%	86,465 $292,000
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $50,106 - $63,824	14,440 Added 15.91%	105,187 $384,000
Q2 2021 Sep 13, 2021	BUY	$3.94 - $4.92 $357,543 - $446,475	90,747 New	90,747 $396,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.